COAG Kronos AI forecast
A 30-trading-day price forecast for Hemab Therapeutics Holdings Inc. (COAG) from Kronos AI, an open-source foundation model trained on candlestick charts.
Kronos AI's median forecast puts Hemab Therapeutics Holdings Inc. at $39.98 on 2026-12-08, +4.1% from the last close of $38.40 on 2026-10-27. Eight out of ten sampled paths end between $36.98 and $46.38, and 6 of the 8 paths finish above today's price.
Forecast path
median, with the 10–90% band of the sampled pathsOpen the interactive forecast → Full analysis of COAG
The forecast, week by week
| Date | Median | Low (10%) | High (90%) |
|---|---|---|---|
| 2026-11-03 | $41.48 | $39.94 | $42.79 |
| 2026-11-10 | $46.52 | $41.25 | $47.15 |
| 2026-11-17 | $46.77 | $42.53 | $48.29 |
| 2026-11-24 | $44.08 | $40.87 | $50.02 |
| 2026-12-01 | $42.57 | $39.70 | $45.36 |
| 2026-12-08 | $39.98 | $36.98 | $46.38 |
What is Kronos AI?
Kronos is an open-source foundation model for financial candlesticks, pre-trained on K-line data from more than 45 exchanges. Gnzub runs it on each stock's last 120 daily bars and samples several possible futures, so the forecast is a range of outcomes rather than one confident line. It is a statistical model, not an analyst: it reads price patterns only and knows nothing about news, earnings or the business.
Questions
- What is the Kronos AI forecast for COAG?
- Kronos AI's median forecast for COAG is $39.98 in 30 trading days, +4.1% from the last close, with a 10–90% range of $36.98 to $46.38.
- Is the COAG Kronos forecast a buy or sell signal?
- No. It is the output of a statistical model that reads price history only. It is not investment advice, and the range shows how uncertain the model is.
- How often is the forecast updated?
- The forecasts are regenerated regularly; this one starts from the close of 2026-10-27.
Kronos forecasts for similar companies
- AMGN — Amgen Inc.
- GILD — Gilead Sciences Inc.
- MRNA — Moderna Inc.
- ARGX — argenx SE American Depositary Shares
- RVMD — Revolution Medicines Inc.
- BIIB — Biogen Inc.